SCHEMBL25300149

SCHEMBL25300149

O=C(NCc1ccnc(Cl)c1)N[C@@H]1C[C@H]1C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 5/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HPGD P15428 4/20 0.41
▸ TAS1R3 Q7RTX0 2/20 0.41
▸ TAS1R1 Q7RTX1 2/20 0.41
▸ TAS1R2 Q8TE23 2/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ POLB P06746 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ CHRM1 P11229 3/20 0.38
▸ HTT P42858 1/20 0.38
▸ NAMPT P43490 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ MAPK3 P27361 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25300150 1.00 EPHX1 (0.47) EPHX1MAPTHPGDTAS1R3TAS1R1
SCHEMBL25878018 1.00 EPHX1 (0.47) EPHX1MAPTHPGDTAS1R3TAS1R1
SCHEMBL25300731 0.87 EPHX1 (0.47) EPHX1MAPTHPGDMEN1POLB
SCHEMBL25882297 0.81 TAS1R3 (0.45) EPHX1MAPTTAS1R3TAS1R1TAS1R2
SCHEMBL25302921 0.80 EPHX1 (0.41) EPHX1MAPTHPGDMEN1POLB
SCHEMBL25877954 0.80 EPHX1 (0.43) EPHX1MAPTNAMPT
SCHEMBL25255261 0.80 EPHX1 (0.43) EPHX1MAPTNAMPT
SCHEMBL25302334 0.80 EPHX1 (0.43) EPHX1MAPTNAMPT
SCHEMBL25262550 0.80 EPHX1 (0.41) EPHX1MAPTHPGDMEN1POLB
SCHEMBL25303815 0.79 LOX (0.43) EPHX1MAPTHPGDMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336571-A1 NOVEL CYCLOPROPYL COMPOUNDS ANGELINI PHARMA S.P.A. (IT) 2024-10-10 — — US claimed
EP-4452944-A1 CYCLOPROPYL COMPOUNDS Icagen, LLC (US) 2024-10-30 — — EP disclosed
US-20240336571-A1 NOVEL CYCLOPROPYL COMPOUNDS ANGELINI PHARMA S.P.A. (IT) 2024-10-10 — — US disclosed
WO-2023121992-A1 CYCLOPROPYL COMPOUNDS ICAGEN, LLC (US) 2023-06-29 — — WO disclosed
WO-2023121992-A1 CYCLOPROPYL COMPOUNDS ICAGEN, LLC (US) 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336571-A1 NOVEL CYCLOPROPYL COMPOUNDS C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR1 EPHX1 1252/4885MAPT 2445/4885HPGD 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback